EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Possible Improvement of Tardive Dyskinesia and Negative Symptoms With Lurasidone Augmentation in a Treatment‐Resistant Schizophrenia Patient

Umut Günay iD, Candost Demiröz iD, Fatma Seher Kocaayan iD, İlay Dalkıran iD, Elif Tatlıdil iD

Case Reports in Psychiatry · 2026-01 · 2026 (1)

DOI: 10.1155/crps/7121649 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Case Reports in Psychiatry, online erschienen am 11.08.2026. Verfasst von Umut Günay und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Kocaeli University, İzmit, Kocaeli, Türkiye, kocaeli.edu.tr. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tardive dyskinesia (TD) is a cluster of symptoms affecting orofacial, truncal, and extremity regions following prolonged exposure to antidopaminergic agents and may be life‐threatening in severe cases. It is most commonly observed in patients receiving long‐term antipsychotic treatment, such as individuals with schizophrenia. Lurasidone is a relatively novel antipsychotic that has been reported to induce tardive syndromes in patients with schizophrenia and bipolar disorder and has also been used as an augmentation strategy in treatment‐resistant schizophrenia. In this report, we present an intriguing case in which TD improved following the addition of lurasidone to the patient’s existing treatment, accompanied by a reduction in negative psychotic symptoms. The patient’s Abnormal Involuntary Movement Scale (AIMS) score decreased from 20 to 8–9 after the initiation and subsequent dose increase of lurasidone. Additionally, the Positive and Negative Syndrome Scale (PANSS) total score decreased from 171 to 148, with particularly notable improvement in the negative symptom subscale. The beneficial effect of lurasidone on TD is hypothesized to be related to various receptor interactions of the current treatment, as well as 5‐HT 2 A antagonism and preferential modulation of dopamine turnover in the prefrontal cortex rather than the striatum, as also observed with clozapine. Further studies are warranted to elucidate the underlying mechanisms of this phenomenon.

Schlagwörter

Stichwörter der Autor:innen

case reportlurasidonenegative symptomstardive dyskinesia

Autor:innen und Institutionen

  • Department of Psychiatry, Kocaeli University, İzmit, Kocaeli, Türkiye, kocaeli.edu.tr.

ORCID-Profile: Umut Günay, Candost Demiröz, Fatma Seher Kocaayan, İlay Dalkıran, Elif Tatlıdil

Zitieren

APA

Günay, U., Demiröz, C., Kocaayan, F. S., Dalkıran, İ., & Tatlıdil, E. (2026). Possible Improvement of Tardive Dyskinesia and Negative Symptoms With Lurasidone Augmentation in a Treatment‐Resistant Schizophrenia Patient. Case Reports in Psychiatry, 2026(1). https://doi.org/10.1155/crps/7121649

Vancouver

Günay U, Demiröz C, Kocaayan FS, Dalkıran İ, Tatlıdil E. Possible Improvement of Tardive Dyskinesia and Negative Symptoms With Lurasidone Augmentation in a Treatment‐Resistant Schizophrenia Patient. Case Reports in Psychiatry. 2026;2026(1). doi:10.1155/crps/7121649

BibTeX
@article{Gnay2026,
  author = {Günay, Umut and Demiröz, Candost and Kocaayan, Fatma Seher and Dalkıran, İlay and Tatlıdil, Elif},
  title = {Possible Improvement of Tardive Dyskinesia and Negative Symptoms With Lurasidone Augmentation in a Treatment‐Resistant Schizophrenia Patient},
  journal = {Case Reports in Psychiatry},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/crps/7121649}
}
Kostenlos starten →